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Abstract 
Pretreatment (18 h) of the bovine aortic endothelial cell line AG4762 to 500 /xM sodium nitroprusside (SNP), glyceryl trinitrate 
(GTN) or 3-morpholino-sydnonimine (SIN-1) significantly inhibited 100 nM bradykinin-stimulated prostacyclin (PGI 2) release. SIN-1 
produced the greatest reduction (67 + 6%), followed by SNP (47 + 12%) and GTN (45 + 9%). Only SIN-I and GTN inhibited basal 
PGI 2 release where again the effect of SIN-1 (66 + 6%) was greater than that of GTN (31 + 15%). There was no effect of SNP on basal 
PGI 2 release. 
We have demonstrated this inhibition of bradykinin-stimulated PGI 2 release is not the result of cell death. In addition, 8-bromo-cyclic 
GMP, whilst having no effect on basal PGI 2 release, demonstrated a small but significant inhibition (15 + 6%) of the enhanced response 
to 100 nM bradykinin. 
These studies may reflect a mechanism by which the release of vasodilators from endothelial cells is altered uring therapy with 
nitrovasodilators and thus may contribute to the development of tolerance to these drugs. 
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1. Introduction 
Prostacyclin (PGI 2) [1] and endothelium-derived r lax- 
ing factor (EDRF) [2], whose biological activity is ac- 
counted for by nitric oxide (NO) [3-5] or a closely related 
molecule such as S-nitroso-L-cysteine [6], are two major 
vasodilator substances released from endothelial cells. Si- 
multaneous release of PGI 2 and NO can be stimulated by 
activation of bradykinin receptors [7] which operate via 
breakdown of phosphatidylinositol [8,9] and a subsequent 
increase in intracellular f ee calcium concentration [10,11 ]
in endothelial cells. The vasodilator effect of PGI 2 is 
mediated by an increase in cyclic AMP in target cells 
[12,13] and that of NO by an increase in cyclic GMP [14]. 
Nitrovasodilator d ugs such as glyceryl trinitrate (GTN) 
are widely used in the treatment of angina pectoris, left 
ventricular failure and congestive heart failure and are 
known to exert their effect through the production of NO 
[15]. The plasma levels of nitrovasodilators are often sus- 
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tained at relatively high levels in the treatment of these 
clinical conditions in particular following their continuous 
infusion or administration by controlled-release formula- 
tions. Tolerance to the effects of nitrovasodilators is a 
widely recognised phenomenon which was first reported 
more than 100 years ago when a reduction in both flushing 
and headaches was observed in patients on nitrate therapy 
[16]. More recently angina pectoris patients treated with 
intravenous infusions of GTN have shown improvement 
after 8 h of continuous therapy but not after 24 h [17]. 
Several processes are likely to be involved though the 
precise mechanisms remain unclear. 
Tolerance appears to be a complex, multifactorial pro- 
cess involving such things as adaptive reflexes and re- 
duced conversion of the nitrovasodilator drugs to NO 
[18,19]. Changes in the responsiveness of smooth muscle 
cells have also been proposed to be involved with de- 
creased levels of soluble guanylate cyclase and increased 
breakdown of cGMP leading to a reduction in the level of 
cGMP [20]. Inhibition of both release and efficacy of the 
endogenous vasodilator NO in rabbit aorta ex vivo has also 
been demonstrated following a chronic diet (16 weeks) 
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containing the NO donor, molsidomine [21]. Furthermore, 
in macrophages NO donors have been shown to irre- 
versibly inhibit NO synthase activity which may constitute 
a regulatory feedback mechanism [22]. 
Previous studies in this laboratory [23] have demon- 
strated that the bradykinin-stimulated production or release 
of PGI 2 from cultured endothelial cells is inhibited during 
acute exposure to the nitrovasodilator d ug sodium nitro- 
prusside (SNP) and enhanced by L-N%nitroarginine which 
inhibits NO formation by endothelial cells [24]. In this 
study we have investigated the effect of chronic exposure 
to three nitrovasodilator d ugs SNP, GTN and 3-morpho- 
lino-sydnonimine (SIN-l) on PGI 2 production or release 
from endothelial cells. Our results demonstrate a signifi- 
cant inhibition of bradykinin-stimulated PGI 2 production 
or release from endothelial cells which may contribute to 
the development of tolerance to nitrovasodilator drugs. 
Preliminary accounts of these findings have already been 
published [25-28]. 
2. Materials and methods 
2.1. Chemicals 
Bradykinin, 8-bromo cyclic GMP, 6-keto-PGF~, 
sodium nitroprusside and sodium thiosulphate were pur- 
chased from Sigma Chemicals. Glyceryl trinitrate 
(Nitronal ®) was obtained from the Queen Elizabeth Hospi- 
tal pharmacy, Birmingham. 3-morpholinosydnonimine 
(SIN-l) was a generous gift from Dr R. Henning, Cassella 
AG, Germany. [3 H]6_keto_PGF l ~ was purchased from New 
England Nuclear Products. 6-keto-PGF~ antibody was a 
gift from Dr S. Barrows, United Medical and Dental 
School, London. 
2.2. Cell culture 
The bovine aortic endothelial cell line AG4762 was 
originally obtained from the Institute of Ageing Cell 
Repository, USA. Endothelial cells (passage 16-23) were 
grown in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% foetal calf serum (FCS) and 1.5 
mM glutamine, maintained at 37°C under an atmosphere of
95% air/5% CO 2. Once confluent, adherent cells were 
detached by trypsinization and reseeded onto 24 × 15 mm 
multiwell plates for PGI 2 release and Trypan blue studies 
and 6 × 36 mm multiwell plates for ATP studies. 
2.3. Nitrovasodilator pretreatment of  AG4762 cells 
SNP, GTN, and SIN-1 are three nitrovasodilator d ugs 
which serve as useful tools for studying the effects of NO. 
Unlike GTN which requires enzymatic onversion to NO 
[29], SNP and SIN-1 release it spontaneously [30,31]. 
Confluent cells were treated with SNP (500 /xM)___ 
sodium thiosulphate (500 /zM), GTN (500 /xM), SIN-1 
(500 /zM) or 8-bromo cyclic GMP (100 /zM) in complete 
medium for 18 h at 37°C under an atmosphere of 95% 
air/5% CO 2 and parallel studies conducted in each case 
with appropriate vehicle. After this time period, the multi- 
well plates were removed to a water-bath at 37°C and the 
medium replaced with DMEM/Ham's  Nutrient Mixture 
F-12 (1:1), buffered to pH 7.4 with 15 mM Hepes and 
without bicarbonate to prevent fluctuations in pH. After a 
period of 1 h, to overcome the interference from shear 
stress-induced PGI 2 release, the medium was removed and 
the cells were incubated for 10 min at 37°C in 
DMEM/Ham's  Nutrient Mixture F-12 (1:1) containing 
saline, 30 nM bradykinin or 100 nM bradykinin in quad- 
ruplicate. 
Time course studies involving 2-min, 5-min and 10-min 
time intervals howed that the level of the stable hydroly- 
sis product of PGI 2, 6-keto-PGFl~ had reached a maxi- 
mum by 5 min and remained unchanged at 10 min (data 
not shown). Subsequent studies were conducted using the 
10-min time interval which was convenient for addition 
and removal of drugs to all 24 wells of a multiwell plate at 
20- to 30-s intervals. Cell supernatants were gently aspi- 
rated and frozen at -20°C for subsequent radioimmunoas- 
say. 
In the case of the 24 h drug-free period, one-third of a 
multiwell plate was treated with SNP (500 p.M) and 
one-third treated with saline in complete medium for 24 h 
at 37°C under an atmosphere of 95% air/5% CO z. After 
this time period, the SNP and saline in complete medium 
were removed and replaced with medium without FCS. 
The remaining third was then treated with SNP (500 /zM) 
in complete medium for 24 h at 37°C under an atmosphere 
of 95% air/5% CO 2. The multiwell plates were removed 
to a water-bath and treated as described above with the 
exception that stimulation was by 30 nM bradykinin alone. 
2.4. Measurement of  PGI e release 
The release of PGI 2 was assessed by radioimmunoassay 
of the cell supernatant for the stable hydrolysis product 
6-keto-PGF l ~ [32] and expressed per mg protein, as deter- 
mined according to the method of Lowry [33], using 
bovine serum albumin as the standard. 
2.5. Nitric oxide chemiluminescent analysis 
Aqueous samples of SNP (500 /zM), GTN (500 /zM), 
SIN-I (500 /~M) and NOy (50 /zM) in the presence of 
endothelial cells were taken over a 19-h period and anal- 
ysed for NO 2 content using the model 270B Nitric Oxide 
Analyser (NOA) from Sievers Instruments. Reduction of 
NO 2 by 1% sodium iodide in glacial acetic acid regener- 
ated the nitric oxide released from the nitrovasodilator 
drugs which was subsequently measured by chemilumines- 
cence. 
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2.6. Assessment of cell viability 
Cell viability was determined both by Trypan blue 
exclusion and adenosine-5'-triphosphate (ATP) levels. 
Multiweli plates containing confluent cells were treated 
with saline, SNP (500 /a,M), GTN (500 /xM), SIN-I (500 
~M) or 8-bromo cGMP (100 /xM). Following an 18-h 
pretreatment, the medium was removed and replaced with 
0.4% Trypan blue solution in phosphate-buffered saline for 
5-15 min. The cells were then examined for cell viability 
using an inverted microscope and cell viability was ex- 
pressed as % total cells unstained. Alternatively, cellular 
ATP levels were determined according to the method 
detailed in the Sigma diagnostic kit (Catalogue number 
366-A) for measurement of adenosine-5'-triphosphate. 
2.7. Statistical analysis 
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Fig. 2. Basal (saline) and bradykinin (30 nM, 100 nM)-stimulated PGI 2 
release, as measured by the levels of its stable hydrolysis product 
6-keto-PGF I ~,, from AG4762 cells following 18 h exposure to saline 
(open columns) or glyceryl trinitrate (500 /xM; vertically hatched 
columns). Each column represents mean + S.E.M. from 6 independent 
experiments. ,A- denotes significant difference (P <0.05) from saline 
control. 
All data are expressed as mean ___ S.E.M. The statistical 
significance (P < 0.05) of the observed reduction in the 
levels of 6-keto-PGF 1 ~ was assessed according to Student's 
t-test for paired data. 
3. Resu l ts  
3.1. The effect of nitrovasodilator pretreatment on PGI 2 
release 
The unstimulated levels of 6-keto-PGFt ~ measured in 
the presence and absence of SNP were 1.6 + 0.8 and 
2.0+0.7 ng/mg protein (n = 6) respectively (Fig. 1). 
Bradykinin at 30 nM and 100 nM stimulated PGI 2 release 
from endothelial cells 4.7 + 0.6- and 3.8 + 0.9-fold (n = 
6) over basal respectively. Basal levels of PGI 2 released 
were not significantly affected by 18 h pretreatment with 
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Fig. 1. Basal (saline) and bradykinin (30 nM, 100 nM)-stimulated PGI 2 
release, as measured by the levels of its stable hydrolysis product 
6-keto-PGFla, from AG4762 cells following 18 h exposure to saline 
(open columns), sodium nitroprusside (500 /xM; right-hatched columns), 
sodium thiosulphate (500 /zM; left-hatched columns) or sodium nitro- 
prusside (500 /xM) and sodium thiosulphate (500 /zM) in combination 
(double-hatched columns). Each column represents mean + S.E.M. from 6 
independent experiments. "Jr and • denote significant (P < 0.05) differ- 
ences from saline and sodium i:hiosulphate controls respectively. 
SNP (500 /zM), sodium thiosulphate (500 /xM) or SNP 
(500/~M) and sodium thiosulphate (500 /~M) in combina- 
tion. The presence of sodium thiosulphate (500/zM) alone 
had no significant effect on bradykinin-stimulated r lease 
of PGI 2. Sodium nitroprusside significantly reduced the 
release of PGI 2 in response to 30 nM bradykinin by 
49_  12% and to 100 nM bradykinin by 47_  12%. The 
inhibition caused by sodium nitroprusside was not restored 
by sodium thiosulphate; in the presence of 500 tzM sodium 
thiosulphate, SNP inhibited the release stimulated by 30 
nM and 100 nM bradykinin by 59_  11% and 62_  11%, 
respectively. 
The unstimulated level of 6-keto-PGF 1 ~ measured in 
the absence of GTN was 8.9 + 1.9 ng/mg protein (n = 6) 
(Fig. 2). This absolute level of 6-keto-PGF l ~ in saline- 
treated endothelial cells was greater in these and subse- 
quent studies with SIN-I and 8-bromo cyclic GMP and 
recovery studies when compared to SNP pretreatment; 
however, the pattern of fold stimulation was very similar. 
Bradykinin at 30 nM and 100 nM stimulated PGI 2 release 
from endothelial cells 3.3 + 0.7- and 2.9 + 0.5-fold (n = 
6) over basal respectively. Both basal and bradykinin- 
stimulated levels of PGI 2 released were significantly inhib- 
ited by pretreatment with GTN for 18 h. Inhibition of basal 
release of PGI 2 from the endothelial cells was by 31 _ 15% 
and inhibition of the responses to 30 nM and 100 nM 
bradykinin by 44 ___ 6% and 45 _ 9% respectively. 
The unstimulated level of 6-keto-PGF l ~ measured in 
the absence of SIN-1 was 9.1 + 2.5 ng/mg protein (n = 6) 
(Fig. 3). Bradykinin at 30 nM and 100 nM stimulated PGI 2 
release from endothelial cells 3.9 + 0.8-fold (n = 6) over 
basal in both instances. Both basal and bradykinin-stimu- 
lated levels of PGI 2 released were significantly inhibited 
by 18 h pretreatment with SIN-1. Basal release of PGI 2 
from the endothelial cells was inhibited by 66_  6% and 
that in response to 30 nM and 100 nM bradykinin by 
75 _ 2% and 67 + 6% respectively. 
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Fig. 3. Basal (saline) and bradykinin (30 nM, 100 nM)-stimulated PGI 2 
release, as measured by the levels of its stable hydrolysis product 
6-keto-PGF I ~,, from AG4762 cells following 18 h exposure to saline 
(open columns) or 3-morpholinosydnonimine (500 /zM; horizontally 
hatched columns). Each column represents mean-t-S.E.M, from 6 inde- 
pendent experiments. ~ denotes ignificantly different (P  < 0.05) from 
saline control. 
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Fig. 5. Basal (saline) and bradykinin (30 nM, 100 nM)-stimulated PGI 2 
release, as measured by the levels of its stable hydrolysis product 
6-keto-PGF~ ,, from AG4762 ceils following 24 h exposure to sodium 
nitroprusside (500/xM) without (hatched columns) or with (solid columns) 
a subsequent 24 h drug-free period. Each column represents mean+ 
S.E.M. from 5 independent experiments. ~r denotes ignificant (P < 0.05) 
reduction from saline control. 
The unstimulated levels of 6-keto-PGF~, measured in 
the presence and absence of 8-bromo cyclic GMP were 
64.1 ___ 23.8 and 51.5 + 15.4 ng/mg protein (n = 5) re- 
spectively (Fig. 4). Bradykinin at 30 nM and 100 nM 
stimulated PGI 2 release from endothelial cells 2 .7_  0.5- 
and 2.8_  0.6-fold (n = 5) over basal respectively. Basal 
levels of PGI z released were not significantly affected by 
18 h pretreatment with 8-bromo cyclic GMP (100 /zM). 
Whilst there was no significant effect on the PGI 2 release 
stimulated by 30 nM bradykinin, a small but significant 
inhibition (15 + 6%) of the response to 100 nM bradykinin 
was observed. 
Recovery from SNP pretreatment was examined follow- 
ing a 24-h drug-free period. Treatment for 24-h periods 
proved more convenient for the recovery studies, and the 
reduction in PGI 2 release produced by SNP (44-t- 12%) 
was not significantly different from that following the 18 h 
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Fig. 4. Basal (saline) and bradykinin (30 nM)-stimulated PGI 2 release, as 
measured by the levels of its stable hydrolysis product 6-keto-PGF I ~, 
from AG4762 cells following 18 h exposure to saline (open columns) or 
8-bromo-cGMP (100 /xM; square hatched columns). Each column repre- 
sents mean + S.E.M. from 5 independent experiments. ,it denotes ignifi- 
cantly different (P  < 0.05) from saline control. 
exposure (49 __+ 12%) (Fig. 5). Pretreatment with SNP at 
500 /xM for 24 h, whilst having no effect on basal release 
of PGI 2, significantly inhibited the release stimulated by 
30 nM bradykinin by 44 -I- 12%. Following a 24-h drug-free 
period, the bradykinin-stimulated release of PGI 2 re- 
mained significantly reduced by 52 + 19%. 
3.2. Nitric oxide chemiluminescent a alysis 
SNP (500 /zM) and GTN (500 /zM) were still generat- 
ing NO at 18 h of incubation in the presence of endothelial 
cells, as measured by an increase in NO 2 of 32% and 19% 
respectively between 18 h and 19 h; a standard solution of 
NO~ remained stable throughout the 19-h time period. 
Within 1 h of incubation the maximum amount of NO 2 
generated by SIN-1 (500/zM) over 19 h had been reached, 
as compared to SNP and GTN which at 1 h had only 
generated 32% and 16% of their maximum respectively 
(Table 1). A slightly raised baseline in the case of SIN-1 
does, however, suggest a small amount of NO is still being 
released which is not distinguishable from the large 
amounts already generated. 
Table 1 
NO release from nitrite (50/~M) and the nitrovasodilator d ugs SNP (500 
/xM), GTN (500 /zM) and SIN-I (500 ~M) in the presence of endothe- 
lial cells at 0, 1, 18 and 19 h, as measured by chemiluminescence 
Treatment nmol NO/well  at time (h) 
0 1 18 19 
Nitrite 52 47 49 47 
SNP 13 8 19 25 
GTN 5 5 26 31 
SIN-1 35 141 142 136 
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3.3. Trypan blue studies 
Exposure to SNP (500 /zM), GTN (500 /zM), SIN-1 
(500 /zM) or 8-bromo cyclic GMP (100 ~M) had no 
effect on cell viability; 80-90% of endothelial cells ex- 
cluded Trypan blue following 18 h treatment with either 
saline, nitrovasodilator d ugs or 8-bromo cyclic GMP. 
3.4. Adenosine-5'-triphosphate (ATP) studies 
The ATP concentration i saline-treated cells was 35.1 
___ 4.5 /zM and this was not significantly altered in cells 
pretreated (18 h) with 500 /zM SNP, 500 /zM GTN, 500 
/zM SIN-I or 100 /zM 8-bromo cyclic GMP, in which the 
ATP levels were 31.9 _+: 1.7 /zM, 32.5 + 0.7 /xM, 34.5 + 
2.8 /zM and 35.8 _ 2.3 /zM respectively. 
4. Discussion 
All three nitrovasodilator d ugs SNP, GTN and SIN-1 
reduced bradykinin-stimulated PGI 2 release from endothe- 
lial cells following 18 h exposure. This may contribute to 
the development of tolerance in nitrovasodilator d ug ther- 
apy and/or the rebound vasoconstriction which is known 
to occur upon withdrawal of nitrovasodilator d ugs. 
SIN-1 produced the greatest reduction, 75% and 67% of 
the response to 30 nM and 100 nM bradykinin respec- 
tively, followed by SNP, 49% and 47%, and then GTN, 
44% and 45%. Only GTN and SIN-1 produced a signifi- 
cant reduction in the basal release of PGI2, where again 
the effect of SIN-1 (66%) was greater than that of GTN 
(31%). Since bradykinin-stimulated PGI 2 release appears 
to have reached its maximum at a concentration of 30 nM, 
the observation of a similar reduction at 100 nM bradykinin 
suggests that the effect is not due to a shift in the bradykinin 
dose-response curve and therefore is unlikely to be the 
result of a decrease in bradykinin affinity. 
Despite the same methodology for the measurement of 
6-keto-PGFl 4, different experiments demonstrated varied 
basal and bradykinin-stimulated PGI 2 release in the ab- 
sence of any pretreatment with nitrovasodilator d ug. There 
appears to be no correlation between passage number of 
the endothelial cells in culture and the control levels of 
PGI z released. It is po,;sible that differences in the me- 
chanical stimulation received by the cells in culture results 
in variable shear stress which stimulates PGI z release. 
The reduction in PGI 2 release following SNP, GTN or 
SIN-1 pretreatment is not due to cell death, the most trivial 
explanation for our observations. In the presence of the 
nitrovasodilator drugs, cell death may potentially arise 
from the cytotoxic agent NO, and in addition cyanide ions 
in the case of SNP [3411. However, the levels of 6-keto- 
PGFj ~ are expressed per mg of protein; AG4762 cells are 
adherent when viable, so cell death should incur a reduc- 
tion in protein content o1' the multiwell. No such reduction 
was observed, and the characteristic ' obblestone' appear- 
ance of confluent cells was maintained following 18 h 
exposure to SNP. In addition, Trypan blue studies demon- 
strated no loss of viability and ATP levels were not altered 
by pretreatment with SNP, GTN or SIN-1. 
The effect of the cyanide ions was considered more 
specifically by studies combining SNP pretreatment with 
sodium thiosulphate which removes the free cyanide ions, 
thereby inactivating them. The significant reduction in 
PGI 2 release was maintained, suggesting the inhibitory 
effect of SNP on PGI 2 release from endothelial cells is not 
the result of any effect of cyanide ions released from this 
nitrovasodilator d ug. 
It is proposed therefore that some mechanism other than 
a cytotoxic action is responsible for the effect of these 
nitrovasodilator drugs on PGI 2 release from endothelial 
cells. Perhaps the reductions in PGI 2 release are mediated 
via cyclic GMP. 
Since nitrovasodilator d ugs produce NO which in turn 
activates soluble guanylate cyclase in endothelial cells 
[35], we have also compared the effect of 18 h exposure to 
the cell-permeable guanosine-3',5'-cyclic monophosphate 
(cGMP) analogue, 8-bromo cyclic GMP, on PGI 2 release 
from the endothelial cells. Pretreatment with 8-bromo 
cyclic GMP (100 /zM), whilst having no effect on basal 
release of PGI z from endothelial cells, significantly inhib- 
ited PGI 2 levels stimulated by 100 nM bradykinin by 15%. 
It may simply be that the concentration of 8-bromo cyclic 
GMP is too low to mimic the elevated levels of cyclic 
GMP resulting from exposure to the nitrovasodilator d ugs 
and this remains to be determined. However, no effect of 
8-bromo cyclic GMP on PGI 2 release was observed 
acutely. In pig aortic endothelial cells, treatment with 30 
/zM 8-bromo cyclic GMP for 20 min had no effect on 
resting or bradykinin (100 nM)-stimulated production of 
6-keto-PGF 1 ~ [36]. The small effect observed in our study 
may result from a higher concentration of 8-bromo cyclic 
GMP (100 ~M) and 18 h pretreatmenc Alternatively, this 
small effect on bradykinin-stimulated PGI z release by 
8-bromo cyclic GMP (15%) as compared to SNP (47%), 
GTN (45%) or SIN-1 (67%) and the lack of effect on basal 
release of PGI 2 in contrast o that observed for GTN and 
SIN-1 may suggest hat, whilst the effect of the nitrova- 
sodilator drugs on PGI 2 release from these endothelial 
cells may be mediated in part by the guanylate cyclase 
pathway, other mechanisms may also be involved. 
The differential effect of SNP, GTN and SIN-1 on the 
basal release of PGI 2 may be the result of less NO 
released from SNP as compared to the two other nitrova- 
sodilator drugs. The order of nitrite generation as deter- 
mined by chemiluminescence was shown to be SIN-1 >> 
GTN > SNP (Table 1). Alternatively, GTN and SIN-1 may 
act through a mechanism independent of the release of NO 
in reducing basal release of PGI 2. The much greater effect 
on bradykinin-stimulated PGI 2 release by SIN-1 as com- 
pared to GTN and SNP correlates well with the order of 
NO release from these nitrovasodilator drugs. Since all 
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three nitrovasodilator drugs reduce PGI 2 release to an 
extent dependent on their NO generation, NO is likely to 
be responsible for this effect. 
The effect of 18 h exposure to SNP is not dependent on 
the continued presence of the drug and seems very pro- 
longed since no reversal of the SNP-mediated inhibition 
was observed following a 24 h drug-free period. It would 
be of interest o determine if the effects of GTN and SIN-I 
on PGI 2 release are also as prolonged, perhaps indicating 
if a common mechanism of inhibition is involved. Prelimi- 
nary studies with SNP have suggested the effect on PGI 2 
release by at least this nitrovasodilator d ug may occur as 
early as 1 h after incubation without any recovery in a 
subsequent 17-h drug-free period (data not shown). At this 
time SNP had only generated 32% of the maximum amount 
of NO 2 measured over 19 h. GTN had also released a 
submaximal (16%) amount of NO after 1 h, whereas SIN-1 
had reached its peak. A similar study investigating the time 
course of effect of GTN and SIN-I has not as yet been 
determined. 
Here we have demonstrated the 18-h exposure to ni- 
trovasodilator drugs reduces bradykinin-stimulated PGI 2 
release from cultured endothelial cells. The inhibitory ef- 
fects of acute exposure to SNP on bradykinin-stimulated 
PGI 2 release previously reported [23] may reflect an en- 
dogenous control mechanism modulating the release of 
dilators from endothelial cells. The more marked and 
prolonged inhibition in the case of these chronic studies, if 
mimicked using primary cell culture, may demonstrate 
how PGI 2 release is altered during treatment with nitrova- 
sodilator drugs, possibly contributing to the development 
of tolerance to these. Depletion of cellular sources of 
arachidonic acid is not likely to be responsible for this 
reduction in PGI 2 release by the nitrovasodilator d ugs; 
bradykinin-stimulated r lease of PGI 2 may be enhanced by 
10 min exposure to L-NC-nitroarginine, which inhibits NO 
synthase [23]. NO is likely to be involved, possibilities 
including a reduced expression and/or activity of COX, as 
recently shown by NO-mediated inhibition of COX-2 [37], 
or of PGI 2 synthetase, and/or a reduction in the effects of 
bradykinin stimulation through calcium or phosphoinosi- 
tide hydrolysis, perhaps reducing PLA 2 activity. The 
molecular mechanisms underlying this inhibition remain to 
be determined. 
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